Make your products visible globally with Elite Membership.
I agree to the terms and conditions
Existing User?
Sign In with Email
Remember Me Forgot Password?
New User?
Enter your registered Email ID to get reset password.
Elite Member
Individual Register
VADODARA, INDIA: Alembic Pharmaceuticals Limited has received approval from the US Food & Drug Administration (USFDA) for Pregabalin Capsules, indicated for management of neuropathic pain associated with certain illnesses. The approved product Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug (RLD), Lyrica Capsules.
Pregabalin Capsule is indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, management of postherpetic neuralgia, adjunctive therapy for the treatment of partial-onset seizures in patients 17 years of age and older, management offibromyalgia and management of neuropathic pain associated with spinal cord injury. Alembic had previously received tentative approval for this ANDA.
Pregabalin Capsules have an estimated market size of US$ 5.47 billion for twelve months ending December 2018 according to IQVIA. Alembic now has a total of 98 ANDA approvals (88 final approvals and 10 tentative approvals) from USFDA.
© Worldofchemicals News
Login
PARIS, FRANCE: The International Energy Agency (IEA) has launched a new online tool that tracks oil & gas-related sources of methane. The new  ...
RAS AL-KHAIMAH, UAE: Thousands of tonnes of camel dung are being used to fuel cement production in the northern United Arab Emirates, cutting emission ...
PITTSBURGH, US: The 20th and 21st centuries have seen an upsurge use of synthetic chemicals worldwide, including pesticides, medications and household ...
NEW DELHI, INDIA: Cadila Healthcare said Zydus' Nesher Pharmaceuticals has received final nod from the US health regulator to market generic version o ...
HOUSTON, US: McDermott International Inc has been awarded a sizeable contract by Argentina-based YPF SA, to provide pre-front-end engineering design ( ...
HYDERABAD, INDIA/ PRINCETON, US: Dr. Reddy’s Laboratories Ltd has launched Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg Extended-Releas ...
Stay updated with the latest chemical industry trends and innovations.
Verification Code has been sent to
Please enter the Verification Code below to verify your Email Address.If you cannot see the email from "noreply@worldofchemicals.com" in your inbox,make sure to check your SPAM Folder